title: Cardiovascular disorders. Primary prevention.
authors.affiliation: University of Oxford, Oxford, UK.
authors.forename: Michael
authors.initials: M
authors.lastname: Murphy
authors.forename: Charles
authors.initials: C
authors.lastname: Foster
authors.forename: Cathie
authors.initials: C
authors.lastname: Sudlow
authors.forename: Julian
authors.initials: J
authors.lastname: Nicholas
authors.forename: Cindy
authors.initials: C
authors.lastname: Mulrow
authors.forename: Andy
authors.initials: A
authors.lastname: Ness
authors.forename: Michael
authors.initials: M
authors.lastname: Pignone
mesh_terms: D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D001572:Benzofurans; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D003131:Combined Modality Therapy; D015444:Exercise; D005247:Feeding Behavior; D006801:Humans; D008019:Life Style; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D016540:Smoking Cessation
chemical_list: C402242:((2-butyl-3-benzofuranyl)-(5-(2-diethylamino)ethoxy)-2-thienyl)methanone; D001572:Benzofurans; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin